| pubmed-article:12271442 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12271442 | lifeskim:mentions | umls-concept:C0013227 | lld:lifeskim |
| pubmed-article:12271442 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:12271442 | lifeskim:mentions | umls-concept:C0032105 | lld:lifeskim |
| pubmed-article:12271442 | lifeskim:mentions | umls-concept:C1527027 | lld:lifeskim |
| pubmed-article:12271442 | lifeskim:mentions | umls-concept:C0178499 | lld:lifeskim |
| pubmed-article:12271442 | lifeskim:mentions | umls-concept:C1948027 | lld:lifeskim |
| pubmed-article:12271442 | lifeskim:mentions | umls-concept:C1516801 | lld:lifeskim |
| pubmed-article:12271442 | lifeskim:mentions | umls-concept:C0599748 | lld:lifeskim |
| pubmed-article:12271442 | lifeskim:mentions | umls-concept:C0936012 | lld:lifeskim |
| pubmed-article:12271442 | lifeskim:mentions | umls-concept:C0008565 | lld:lifeskim |
| pubmed-article:12271442 | lifeskim:mentions | umls-concept:C0392762 | lld:lifeskim |
| pubmed-article:12271442 | lifeskim:mentions | umls-concept:C0679622 | lld:lifeskim |
| pubmed-article:12271442 | lifeskim:mentions | umls-concept:C0205314 | lld:lifeskim |
| pubmed-article:12271442 | lifeskim:mentions | umls-concept:C0348080 | lld:lifeskim |
| pubmed-article:12271442 | lifeskim:mentions | umls-concept:C1527178 | lld:lifeskim |
| pubmed-article:12271442 | lifeskim:mentions | umls-concept:C0386319 | lld:lifeskim |
| pubmed-article:12271442 | pubmed:issue | 9 | lld:pubmed |
| pubmed-article:12271442 | pubmed:dateCreated | 2002-9-24 | lld:pubmed |
| pubmed-article:12271442 | pubmed:abstractText | Kahalalide F (KF) is a novel cyclic depsipeptide anticancer drug, which has shown anticancer activity both in vitro and in vivo especially against human prostate cancer cell lines. To characterize the pharmacokinetics of KF during a phase I clinical trial in patients with androgen refractory prostate cancer, a method was developed and validated for the quantitative analysis of KF in human plasma using high-performance liquid chromatography (HPLC) coupled to positive electrospray ionization tandem mass spectrometry (ESI-MS/MS). Microbore reversed-phase liquid chromatography (LC) performed with mobile phases containing trifluoroacetic acid, an additive commonly used for separating peptides, resulted in substantial suppression of the signal for KF on ESI-MS/MS. An alternative approach employing a basic mobile phase provided an excellent response for KF when detected in the positive ion mode. Plasma samples were prepared for LC MS/MS by solid-phase extraction on C(18) cartridges. The LC separation was performed on a Zorbax Extend C(18) column (150 x 2.1 mm i.d., particle size 5 micro m) with acetonitrile -10 mM aqueous ammonia (85 : 15, v/v) as the mobile phase, at a flow-rate of 0.20 ml min(-1). A butyric acid analogue of KF was used as the internal standard. The lower limit of quantitation (LLQ) using a 500 micro l sample volume was 1 ng ml(-1) and the linear dynamic range extended to 1000 ng ml(-1). The inter-assay accuracy of the assay was -15.1% at the LLQ and between -2.68 and -9.05% for quality control solutions ranging in concentration from 2.24 to 715 ng ml(-1). The inter-assay precision was 9.91% or better at these concentrations. The analyte was stable in plasma under all relevant conditions evaluated and for a period of 16 h after reconstituting plasma extracts for LC analysis at ambient temperature. | lld:pubmed |
| pubmed-article:12271442 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12271442 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12271442 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12271442 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12271442 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12271442 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12271442 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12271442 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12271442 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:12271442 | pubmed:issn | 1076-5174 | lld:pubmed |
| pubmed-article:12271442 | pubmed:author | pubmed-author:RodriguezII | lld:pubmed |
| pubmed-article:12271442 | pubmed:author | pubmed-author:JimenoJ MJM | lld:pubmed |
| pubmed-article:12271442 | pubmed:author | pubmed-author:BeijnenJ HJH | lld:pubmed |
| pubmed-article:12271442 | pubmed:author | pubmed-author:RosingHH | lld:pubmed |
| pubmed-article:12271442 | pubmed:author | pubmed-author:SupkoJ GJG | lld:pubmed |
| pubmed-article:12271442 | pubmed:author | pubmed-author:López-LázaroL... | lld:pubmed |
| pubmed-article:12271442 | pubmed:author | pubmed-author:StokvisEE | lld:pubmed |
| pubmed-article:12271442 | pubmed:author | pubmed-author:SchellensJ... | lld:pubmed |
| pubmed-article:12271442 | pubmed:copyrightInfo | Copyright 2002 John Wiley & Sons, Ltd. | lld:pubmed |
| pubmed-article:12271442 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12271442 | pubmed:volume | 37 | lld:pubmed |
| pubmed-article:12271442 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12271442 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12271442 | pubmed:pagination | 992-1000 | lld:pubmed |
| pubmed-article:12271442 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:12271442 | pubmed:meshHeading | pubmed-meshheading:12271442... | lld:pubmed |
| pubmed-article:12271442 | pubmed:meshHeading | pubmed-meshheading:12271442... | lld:pubmed |
| pubmed-article:12271442 | pubmed:meshHeading | pubmed-meshheading:12271442... | lld:pubmed |
| pubmed-article:12271442 | pubmed:meshHeading | pubmed-meshheading:12271442... | lld:pubmed |
| pubmed-article:12271442 | pubmed:meshHeading | pubmed-meshheading:12271442... | lld:pubmed |
| pubmed-article:12271442 | pubmed:meshHeading | pubmed-meshheading:12271442... | lld:pubmed |
| pubmed-article:12271442 | pubmed:meshHeading | pubmed-meshheading:12271442... | lld:pubmed |
| pubmed-article:12271442 | pubmed:meshHeading | pubmed-meshheading:12271442... | lld:pubmed |
| pubmed-article:12271442 | pubmed:meshHeading | pubmed-meshheading:12271442... | lld:pubmed |
| pubmed-article:12271442 | pubmed:meshHeading | pubmed-meshheading:12271442... | lld:pubmed |
| pubmed-article:12271442 | pubmed:meshHeading | pubmed-meshheading:12271442... | lld:pubmed |
| pubmed-article:12271442 | pubmed:meshHeading | pubmed-meshheading:12271442... | lld:pubmed |
| pubmed-article:12271442 | pubmed:year | 2002 | lld:pubmed |
| pubmed-article:12271442 | pubmed:articleTitle | Quantitative analysis of the novel depsipeptide anticancer drug Kahalalide F in human plasma by high-performance liquid chromatography under basic conditions coupled to electrospray ionization tandem mass spectrometry. | lld:pubmed |
| pubmed-article:12271442 | pubmed:affiliation | Department of Pharmacy and Pharmacology, Slotervaart Hospital/The Netherlands Cancer Institute, Louwesweg 6, 1066 EC Amsterdam, The Netherlands. | lld:pubmed |
| pubmed-article:12271442 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12271442 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:12271442 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
